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Abstract
Cognitive impairments are a common consequence of traumatic brain injury (TBI). The hippo-
campus is a subcortical structure that plays a key role in the formation of declarative memories
and is highly vulnerable to TBI. The α7 nicotinic acetylcholine receptor (nAChR) is highly
expressed in the hippocampus and reduced expression and function of this receptor are
linked with cognitive impairments in Alzheimer’s disease and schizophrenia. Positive allosteric
modulation of α7 nAChRs with AVL-3288 enhances receptor currents and improves cognitive
functioning in naïve animals and healthy human subjects. Therefore, we hypothesized that
targeting the α7 nAChR with the positive allosteric modulator AVL-3288 would enhance cogni-
tive functioning in the chronic recovery period of TBI. To test this hypothesis, adult male Spra-
gue Dawley rats received moderate parasagittal fluid-percussion brain injury or sham surgery.
At 3 months after recovery, animals were treated with vehicle or AVL-3288 at 30 min prior to
cue and contextual fear conditioning and the water maze task. Treatment of TBI animals with
AVL-3288 rescued learning and memory deficits in water maze retention and working mem-
ory. AVL-3288 treatment also improved cue and contextual fear memory when tested at 24 hr
and 1 month after training, when TBI animals were treated acutely just during fear conditioning
at 3 months post-TBI. Hippocampal atrophy but not cortical atrophy was reduced with AVL-
3288 treatment in the chronic recovery phase of TBI. AVL-3288 application to acute hippo-
campal slices from animals at 3 months after TBI rescued basal synaptic transmission deficits
and long-term potentiation (LTP) in area CA1. Our results demonstrate that AVL-3288
improves hippocampal synaptic plasticity, and learning and memory performance after TBI in
the chronic recovery period. Enhancing cholinergic transmission through positive allosteric
modulation of the α7 nAChR may be a novel therapeutic to improve cognition after TBI.
Introduction
There are an estimated 3.17 million people in the US coping with long-term disabilities due to
TBI, resulting in an economic burden exceeding $56 billion annually [1, 2]. Nearly 80% of
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people who have sustained a TBI report learning and memory impairments in the months to
years after the initial brain trauma [3]. The hippocampus, an area of the brain important for
declarative memory formation, is highly vulnerable and exhibits a significant degree of pathol-
ogy after TBI [4, 5]. Although there is some understanding of the changes within the hippo-
campus as a consequence of TBI, no FDA-approved pharmacological therapies are available to
ameliorate cognitive deficits in the chronic recovery phase of TBI [6]. The development of a
robust, efficacious therapeutic to target these alterations in the hippocampus and improve
learning and memory is an area that needs investigation.
Neuronal circuits involved in cognition, attention and concentration contain nicotinic cho-
linergic synapses [7, 8]. These circuits are altered with age and are associated with cognitive
decline and Alzheimer’s disease [9, 10]. The most abundant nAChRs in the brain are the α7 and
α4β2 subunit-containing receptors [11, 12]. In particular, the α7 nAChR is found both pre- and
post-synaptically on excitatory neurons in the hippocampus as well as on interneurons [13, 14].
The α7 nAChR modulates fast synaptic transmission, neurotransmitter release and synaptic
plasticity due to its ability to gate calcium flux [15–17]. Activation of α7 nAChRs converts
short-term potentiation into LTP, which is particularly relevant for experimental TBI, where
short-term potentiation typically remains intact, but maintenance of LTP is impaired [18–21].
Numerous preclinical studies have established that in the days to weeks after TBI, there is a
decrease in cholinergic signaling [22–24]. There is reduced high-affinity choline uptake [25],
decreased choline acetyltransferase activity [26], acute reductions in vesicular acetylcholine
transporter [27] and transient depression of cholinesterase activity in the hippocampus [28].
At the receptor level, there is a loss of up to 50% of α7 nAChRs after controlled cortical impact
[29, 30]. This decrease is accompanied by a bilateral loss of cholinergic neurons and their axo-
nal projections [31]. Decreased cholinergic signaling has been reported in human TBI studies
as well, lasting for at least one year after trauma [32, 33]. Although cholinergic signaling is
decreased chronically after TBI, it is not completely absent. This suggests that therapeutics that
enhance the remaining endogenous cholinergic activity may be efficacious.
It is well established that agonists of cholinergic receptors rescue memory impairments in pre-
clinical models of TBI [34–36]; however, results with cholinesterase inhibitors have had mixed suc-
cess [37–46]. Cholinesterase inhibitors act by blocking the hydrolysis of acetylcholine which in
turn increases acetylcholine levels. Chronic administration of either full or partial agonists, or cho-
linesterase inhibitors may be limited by the natural adaptation (e.g., receptor desensitization) of the
brain to increased levels of agonist. A method to preserve spatial and temporal integrity of cholin-
ergic signaling is to utilize allosteric modulators. Positive allosteric modulators of the α7 nAChR
bind the receptor, but only enhance receptor current when the receptor is bound to its agonist.
Positive allosteric modulators for α7 nAChRs are divided into two types, depending on whether
they have no effect on receptor desensitization kinetics (type I) or slow desensitization (type II).
This differentiation of mechanism is important since the α7 nAChR gates calcium flux and natu-
rally desensitizes rapidly. In this study, we investigated the actions of a type I positive allosteric
modulator of the α7 nAChR, AVL-3288, on outcome in the chronic recovery phase of TBI [47].
Materials and methods
Animals
All animal procedures were in compliance with the NIH Guide for the Care and Use of Labora-
tory Animals and approved by the University of Miami Animal Care and Use Committee. Adult
male Sprague-Dawley rats (n = 94 total, 2–3 months old, Charles Rivers Laboratories) were
maintained on a 12/12 hr light/dark cycle and had free access to food and water. To determine
the minimum number of animals needed for these studies, a power analysis was prospectively
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performed to detect a 20% difference in water maze probe trial performance between groups at
80% power with a significance level of 0.05 [19]. A sample size of 11 animals/group was obtained.
The effect size for our observed differences in the water maze probe trial was 1.28, recent recall
of contextual fear conditioning was 1.39, remote recall of contextual fear conditioning was 0.92
and LTP expression at 30–60 post-tetanization was 1.27. These large effect sizes indicate that our
sample size was adequate for the main objective of this study, to determine if AVL-3288
improved hippocampal learning and memory and LTP in TBI animals.
Fluid-percussion injury surgery
Animals were randomly assigned prior to the experiment to receive either moderate parasagit-
tal fluid-percussion injury (FPI) or sham surgery, and either treatment with vehicle or AVL-
3288. Under deep anesthesia (3% isoflurane, 70% N2O, and 30% O2, maintained at 1–2% iso-
flurane, 70% N2O, and 30% O2), a 4.8 mm craniotomy was made at 3.8 mm posterior to
bregma, 2.5 mm right from midline and a beveled 18 gauge syringe hub was secured to the cra-
niotomy site. At 12–16 hr after the craniotomy, animals were re-anesthetized, intubated and
mechanically ventilated (Stoelting) with 1–2% isoflurane, 70% N2O, and 30% O2. All animals
received a catheter in the tail artery for physiological monitoring. Rocuronium (10 mg/kg) was
administered through the tail artery to facilitate ventilation, and penicillin G potassium
(20,000 IU/kg, intramuscular) was given during the surgery. A moderate (1.9±0.1 atm) fluid-
percussion pulse (14–16 msec duration) was delivered to the right parietal cortex. Sham-oper-
ated rats received all surgical manipulations except for the fluid pulse. Anesthesia duration
during the surgeries was monitored to ensure that the cumulative duration of anesthetic was
consistent across treatment groups. Each animal received two anesthesia rounds. The anes-
thetic duration for each surgery was less than 1 hr, and animals were not behaviorally tested
until 3 months after the final surgery. Rectal and temporalis muscle thermistors were used to
maintain body and head temperatures between 36.6–37.2˚C. Mean arterial blood pressure
(MAPB) was monitored continuously during the surgery with a transducer connected to the
tail artery catheter and LabChart 7 software (ADInstruments). Blood gases and blood pH were
measured from blood harvested from the tail artery with a blood gas analyzer (ABL800 Flex,
Radiometer America). Atmospheres of pressure were measured using a transducer connected
to the fluid percussion injury shaft and LabChart 7 software. Blood gases (pO2 and pCO2),
blood pH and MABP were maintained within normal physiological ranges (Table 1). No sig-
nificant differences were observed in these physiological measures (body weight, MABP, blood
pO2, blood pCO2, blood pH, body temperature, head temperature) between Sham+Vehicle,
Sham+AVL-3288, TBI+Vehicle or TBI+AVL-3288 treated animals. Buprenorphine (0.01 mg/
kg, subcutaneously) was administered at the completion of the surgery. Exclusion criteria
were: mortality, >15% loss of body weight, non-resolving infection at a surgical site, inability
to feed or drink, motor paralysis, listlessness, self-mutilation, excessive grooming leading to
loss of dermal layers, excessive spontaneous vocalization when touched, or poor grooming
habits. Animals were monitored daily after surgery for the first 2 days, then evaluated and
weighed every 2 weeks until perfusion or decapitation. Attrition for sham surgery was 0% and
for TBI surgery was 1% (1 animal, which died at the time of surgery due to lung edema). Inves-
tigators were blind to the animal surgery allocation and drug treatment for all behavior,
electrophysiology and histology analyses.
Drug administration
AVL-3288 was synthesized as described [48]. AVL-3288 (0.3 mg/kg) or vehicle (2% DMSO,
8% Solutol and 90% saline, 1 ml/kg) were administered intraperitoneally at 30 min prior to:
α7 nAChR modulation for treating TBI
PLOS ONE | https://doi.org/10.1371/journal.pone.0223180 October 3, 2019 3 / 20
training on cue and contextual fear conditioning, water maze training days 1–4, both testing
days for working memory, and shock threshold testing. Each animal received a total of 8 vehi-
cle or AVL-3288 treatments. Retention at 24 hr after cue and contextual fear conditioning and
the probe trial of the water maze were assessed without drug treatment to evaluate whether
AVL-3288 had effects on memory retention beyond the acute treatment period. Hippocampal
slices were treated with AVL-3288 (1 μM) or vehicle (0.01% DMSO) for 10 min prior to high-
frequency tetanization and for 30 min after LTP induction.
Pharmacokinetic analysis
Naïve, non-injured animals received AVL-3288 (in 2% DMSO, 8% Solutol, 90% saline, 0.3
mg/kg, intraperitoneally) and then were deeply anesthetized (3% isoflurane, 70% N2O, and
30% O2) from 15 min to 24 hr after treatment. Whole brain tissue and trunk blood were col-
lected. Plasma was prepared with 0.5M K+-EDTA, and centrifuged at 3000 x g for 10 min at
4˚C. The brains were extracted with ethyl acetate. AVL-3288 levels were measured by LC-MS/
MS. The chromatographic separation was performed using a Luna, C8, 2.0 x 150 mm 5 μm col-
umn (Phenomenex) with 75:25 acetonitrile:0.1% formic acid in water mobile phase with a flow
rate of 0.3 ml/min at 40˚C with an Agilent 1100/1200 HPLC and an Agilent 6410B QQQ Mass
Spectrometer (Agilent Technologies). The mass spectrometer parameters were: FV 100, CE 8,
with positive ion monitoring. The pharmacokinetic data were analyzed by standard methods
using Agilent Mass Hunter Software Version 4.0, SAS JMP Version 7 and Microsoft Excel.
Table 1. Physiological data.
Parameter Treatment At surgery At perfusion Parameter Treatment 15 min
prior to FPI
15 min
post-FPI
Weight
(gm)
Sham+Vehicle 359.3±10.8 666.0±22.6 ��� MABP
(mmHg)
Sham+Vehicle 121.3±3.6 121.6±2.2
Sham+AVL-3288 363.4±16.5 643.5±19.0 ��� Sham+AVL-3288 122.8±4.1 111.2±4.2
TBI+Vehicle 349.5±10.8 623.5±20.9 ��� TBI+Vehicle 115.7±3.5 113.0±2.2
TBI+AVL-3288 360.3±13.0 614.8±22.0 ��� TBI+AVL-3288 116.8±4.5 110.8±3.8
ATM Sham+Vehicle N/A Blood pO2
(mmHg)
Sham+Vehicle 153.4±6.6 150.7±5.0
Sham+AVL-3288 N/A Sham+AVL-3288 158.0±9.9 147.8±6.9
TBI+Vehicle 1.9±0.0 TBI+Vehicle 153.9±6.8 136.3±5.0 �
TBI+AVL-3288 1.9±0.0 TBI+AVL-3288 149.8±6.5 134.5±5.6 ��
Parameter Treatment 15 min
prior to FPI
15 min
post-FPI
Parameter Treatment 15 min
prior to FPI
15 min
post-FPI
Blood pCO2
(mmHg)
Sham+Vehicle 41.9±1.1 40.2±0.9 � Head
temperature
(ºC)
Sham+Vehicle 36.6±0.0 36.8±0.0��
Sham+AVL-3288 39.8±0.9 38.1±0.7 � Sham+AVL-3288 36.7±0.0 36.8±0.0 ��
TBI+Vehicle 38.5±0.8 36.8±0.5 � TBI+Vehicle 36.7±0.0 36.8±0.0
TBI+AVL-3288 39.0±0.7 37.2±0.5 � TBI+AVL-3288 36.6±0.1 36.7±0.0
Blood pH Sham+Vehicle 7.4±0.0 7.5±0.0 �� Body
temperature
(ºC)
Sham+Vehicle 36.8±0.0 36.7±0.0
Sham+AVL-3288 7.5±0.0 7.5±0.0 Sham+AVL-3288 36.7±0.0 36.8±0.0
TBI+Vehicle 7.4±0.0 7.5±0.0 TBI+Vehicle 36.8±0.1 36.8±0.0
TBI+AVL-3288 7.5±0.0 7.5±0.0 TBI+AVL-3288 36.8±0.1 36.8±0.0
ATM: atmospheres of pressure, MABP: mean arterial blood pressure, N/A: not applicable, pO2: partial arterial oxygen pressure, pCO2: partial arterial carbon dioxide
pressure.
�p<0.05
��p<0.01
���p<0.001 vs. at surgery or 15 min prior to FPI, repeated measures two-way ANOVA with Tukey’s HSD post-hoc test. Mean±SEM, n = 10 Sham+Vehicle, n = 8 Sham
+AVL-3288, n = 11 TBI+Vehicle, n = 11 TBI+AVL-3288.
https://doi.org/10.1371/journal.pone.0223180.t001
α7 nAChR modulation for treating TBI
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Fear conditioning
At 3 months post-surgery, animals were trained and tested for cue and contextual fear condi-
tioning [19]. Animals were first habituated for 10 min to a cage equipped with a shock grid
floor (Coulbourn Instruments). At 24 hr after habituation, animals were trained by being
placed in the apparatus for 120 s, and then a 30 s tone (75 dB, 2.8 kHz) was delivered that co-
terminated with a 1 mA, 1 s foot shock. Animals remained in the apparatus for 60 s after the
foot shock. At 24 hr and 1 month after training, animals were placed in the apparatus and
freezing was measured for 5 min to assess contextual fear conditioning. Cue fear conditioning
was evaluated 1 hr after assessment of contextual fear by placing the animals in an altered
chamber. The tone (75 DB, 2.8 kHz) was played for 60 s and freezing was measured. Freezing
behavior was quantified by video analysis (FreezeFrame 3.32, Coulbourn Instruments). Shock
threshold was assessed 1 day after final cue and contextual fear conditioning testing (4 months
post-surgery). Animals received a 1 s foot shock every 30 s in increments of 0.02 mA beginning
at 0.1 mA. Minimum shock intensity to elicit a flinch, jump, or vocalization was measured.
Water maze
At 1 week after cue and contextual fear conditioning (13 weeks post-surgery), animals were
next trained in the water maze for 4 trials/day (60 s maximum trial duration) over 4 days with
an inter-trial interval of 4–6 min [19]. Path length to reach the platform was measured by
video analysis (EthoVision XT 10, Noldus Information Technology). At 24 hr after the final
acquisition day, a probe trial (60 s duration) was given with the platform removed. The
amount of time spent in each quadrant of the pool was measured.
At 1 week after water maze training and testing (14 weeks post-surgery), working memory
was assessed in the water maze [19]. Animals received 2 days of testing with the platform
remaining invariant between each pair of trials (5 s delay between trials, 60 s maximum trial
duration). Each day consisted of 4 paired trials (4–6 min between each trial pair). Path length
to reach the platform was measured. Data from day 2 were analyzed.
Histology
At the completion of behavioral testing (4–5 months post-surgery), animals were deeply anesthe-
tized (3% isoflurane, 70% N2O, 30% O2) and transcardially perfused with saline and 4% parafor-
maldehyde in 0.1M phosphate buffer, pH 7.4. Brains were paraffin-embedded and sectioned
(10 μm thick, 150 μm apart) and stained with hematoxylin and eosin (H&E) plus Luxol fast blue
as previously described [19]. Sections were imaged at 7200 dpi (3.5 μm/pixel) with a Quick Scan
PathScan Enabler IV 3.60.0.12 (Meyer Instruments). The cortex and hippocampus were con-
toured between bregma levels -3.3 to -6.8 mm using Neurolucida 11.11.2 (MicroBrightField).
Atrophy was quantified by subtracting the contralateral volume from the ipsilateral volume and
normalizing to the contralateral volume. Images were obtained on an Olympus BX51TRF micro-
scope (Olympus America) with a 20× objective and stitched with StereoInvestigator 5.65 software
(MicroBrightField). Three-dimensional projections were rendered in NeuroLucida 11.11.2. To
construct the 3-dimensional projections, the outer shells of the brain contours were aligned using
the rhinal fissures and the midline. Cortical contours were aligned using the retrosplenial granu-
lar area and hippocampal contours were aligned using the habenular nuclei and dentate gyrus.
Electrophysiology
At 3 months post-surgery, animals were deeply anesthetized (3% isoflurane, 70% N2O, and
30% O2), decapitated and the hippocampus was quickly isolated from the brain. Transverse
α7 nAChR modulation for treating TBI
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slices (400 μm thick) were prepared as previously described [19]. Recordings were made in
aCSF: 125 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 25 mM NaHCO3, 10 mM D-glucose, 2
mM CaCl2, 1 mM MgCl2, saturated with 95% O2/5% CO2 at room temperature. The Schaffer
collateral pathway was stimulated with a platinum-iridium cluster stimulating electrode (tip
diameter 25 μm, FHC). Field excitatory postsynaptic potentials (fEPSPs) and fiber volleys were
recorded from CA1 stratum radiatum with glass micropipettes filled with 2 M NaCl (1–3 MO)
using a Multiclamp 700B amplifier (Axon Instruments). Signals were low pass filtered at 2 kHz
and digitized at 20 kHz with a Digidata 1440A interface and analyzed with pClamp 11 (Axon
Instruments). Input-output (I-O) curves were generated by stimulating from 20–240 μA.
Paired-pulse facilitation (PPF) was measured with stimulus intervals from 12.5–250 msec,
with stimulation intensity set at 40–50% of the maximum fEPSP. Prior to LTP induction, base-
line responses were recorded at 40–50% of the maximum fEPSP at 0.033 Hz for at least 20
min. LTP was induced by high-frequency stimulation (HFS) using a single train of 100 pulses
delivered at 100 Hz at test stimulation intensity. AVL-3288 (1 μM) or vehicle (0.01% DMSO)
were bath-applied in aCSF beginning 10 min prior to HFS and for 30 min after HFS. The teta-
nization response was analyzed by integrating the entire HFS response and also by integrating
the depolarization during last 50 msec of the HFS to determine steady-state depolarization
[49]. Synaptic fatigue was calculated by measuring each fEPSP during the HFS and normaliz-
ing this to the first fEPSP of the HFS [50].
Statistical analysis
Data presented are mean ± SEM. Significance was designated at p<0.05. Statistical analyses
were performed in GraphPad Prism 7.0 and SigmaPlot 12.0. Two-way ANOVA and repeated
measures two-way ANOVA were used to determine group differences with the factors surgery
x drug treatment or animal group x time/trial/current intensity. Tukey’s HSD post-hoc tests
were used when significant interactions were observed. Simple linear regression fits were used
to evaluate the fiber volley amplitude and fEPSP slope and the slopes were compared with a
two-way ANOVA with the factors surgery x drug treatment.
Results
AVL-3288 levels in brain and plasma
AVL-3288 selectively enhances wildtype, human α7 nAChR currents evoked by nicotine in
Xenopus oocytes at a dose as low as 0.1 μM with an Imax of 3 μM [47]. To determine if AVL-
3288 could be singly administered systemically and reach levels in the brain that are effective
in modulating α7 nAChR currents, levels of AVL-3288 in the brain and plasma were measured
after intraperitoneal administration (Fig 1). Naïve, non-injured rats received AVL-3288 (0.3
mg/kg, intraperitoneally) and then plasma and brain tissue were analyzed using LC-MS/MS as
previously described [51]. AVL-3288 reached 3 μM in total brain tissue within 30 min of
administration and peaked at 4.6 μM by 90 min. Levels returned to baseline by 24 hr after
administration. Based on these results and a previous study demonstrating that the minimum
effective dose to improve radial arm maze memory in rats was 0.3 mg/kg AVL-3288, we chose
to use this dose in our TBI study [47].
Hippocampal-dependent learning and memory ability is improved with
AVL-3228 treatment after TBI
This preclinical model of TBI is characterized by persistent hippocampal-dependent learning
and memory deficits in contextual fear conditioning and the water maze task [19, 52]. To
α7 nAChR modulation for treating TBI
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determine if AVL-3288 could rescue these cognitive deficits, animals were treated with AVL-
3288 or vehicle at 30 min prior to cue and contextual fear conditioning (Fig 2). Since activation
of α7 nAChRs converts short-term potentiation in hippocampal slices to LTP, we chose to
treat animals during training, but not during testing [18–21]. No significant differences were
observed in cue and contextual fear conditioning between sham animals treated with vehicle
versus AVL-3288. In TBI animals, AVL-3288 significantly improved both cue and contextual
fear conditioning when assessed 24 hr after training for recent recall (surgery x drug treatment
interaction: cue F(1,36) = 4.29, p = 0.045; context F(1,36) = 8.32, p = 0.007). The effects on fear
memory were persistent as shown by a significant improvement in remote recall assessed 1
month after training (surgery x drug treatment interaction: cue F(1,36) = 6.75, p = 0.013; context
F(1,36) = 6.59, p = 0.015).
Next, to determine if AVL-3288 improves other types of hippocampal-dependent learning,
animals were tested in the water maze to find a hidden platform using spatial cues (Fig 3A–
3E). Animals were pretreated with AVL-3288 at 30 min prior to water maze acquisition for 4
days. AVL-3288 treatment did not significantly reduce the path length to find the platform on
the final day of acquisition (day 4) in TBI animals as compared to vehicle-treated TBI animals.
Retention at 24 hr after the last acquisition day was assessed without drug treatment to deter-
mine if AVL-3288 needed to be present for an effect on memory retention. TBI animals treated
with vehicle demonstrated no significant preference for the target quadrant. In contrast, sham
animals treated with either vehicle or AVL-3288, and TBI animals treated with AVL-3288
searched the target quadrant significantly more than the other quadrants, indicating that spa-
tial memory was improved with AVL-3288 treatment (surgery x drug treatment interaction
for time in target quadrant: F(1,36) = 5.00, p = 0.032).
Assessment of spatial working memory revealed similar improvements with AVL-3288
treatment (Fig 3F). Animals were trained on a delay match-to-sample task in the water maze,
with 5 s between a location and match trial and the platform remaining in the same location
only during pairs of trials. Sham+Vehicle, Sham+AVL-3288 and TBI+AVL-3288 treated ani-
mals had significantly shorter path lengths to find the platform on the match trial as compared
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Fig 1. Pharmacokinetics. Levels (μM) of AVL-3288 in the brain and plasma. Naïve, non-injured animals were treated
with AVL-3288 intraperitoneally (0.3 mg/kg in 2% DMSO, 8% Solutol, 90% saline). AVL-3288 was measured in total
brain tissue and plasma by LC-MS/MS. Mean ± SEM, n = 3/group.
https://doi.org/10.1371/journal.pone.0223180.g001
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to the location trial, indicative of working memory, whereas TBI+Vehicle treated animals had
significantly longer paths to find the platform on the match trial (animal group x trial interac-
tion: F(3,32) = 3.25, p = 0.035).
Effects on hippocampal atrophy with AVL-3288 treatment after TBI
Previous studies have demonstrated that choline, nicotine and donepezil administration not
only improve cognition, but also reduce lesion volume and rescue CA1 neuronal loss after TBI
[34, 36, 53, 54]. At the completion of behavioral testing, we evaluated cortical and hippocampal
atrophy which is characteristic of this preclinical model of TBI at this recovery time point [55]
(Fig 4). Cortical atrophy in the ipsilateral parietal cortex was similar between TBI animals
treated with vehicle and AVL-3288. However, hippocampal atrophy on the ipsilateral side was
modestly reduced in TBI animals treated with AVL-3288 as compared to TBI animals treated
with vehicle (surgery x drug treatment interaction: F(1,36) = 5.81, p = 0.021).
Positive allosteric modulation of α7 nAChR enhances basal synaptic
transmission and LTP after chronic TBI
To assess electrophysiological changes with AVL-3288 treatment, a separate cohort of animals
received sham surgery or moderate FPI and then were allowed to recover without any
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tasks. Animals received AVL-3288 or vehicle treatment 30 min prior to training for fear conditioning (Fear cond), on the 4 training days of
the water maze, on each day of training for working memory (Work mem), and during shock threshold testing (ST) for a total of 8
treatments over the course of 1 month as depicted by the arrows. Animals were tested without AVL-3288 treatment for memory retention
of fear conditioning at 24 hr and 1 month post-training (Fear ret) and on the probe trial for the water maze at 24 hr post-training. B)
Recent recall of fear conditioning at 24 hr after training. ��p<0.01, ���p<0.001 vs. Training, ap<0.05, cp<0.001 vs. TBI+Vehicle, repeated
measures two-way ANOVA with Tukey’s HSD post-hoc test. C) Assessment of fear conditioning at one month after training to evaluate
remote recall of fear memory. �p<0.05, ��p<0.01, ���p<0.001 vs. TBI+Vehicle, two-way ANOVA with Tukey’s HSD post-hoc test.
Mean ± SEM, n = 10 Sham+Vehicle, n = 8 Sham+AVL-3288, n = 11 TBI+Vehicle, n = 11 TBI+AVL-3288.
https://doi.org/10.1371/journal.pone.0223180.g002
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treatment. At 3 months post-surgery, the time point corresponding to the beginning of behav-
ioral testing, acute hippocampal slices were generated and recordings were made in stratum
radiatum of area CA1 (Fig 5). Hippocampal slices were treated with vehicle or AVL-3288
(1 μM). Afferent fiber excitability as measured by the fiber volley amplitude was unaltered
after TBI, but synaptic strength as assessed with the fEPSP slope was significantly depressed
(animal group x current intensity interaction: F(30,195) = 2.79, p<0.001). Analysis of the rela-
tionship between the fEPSP slope and fiber volley amplitude indicated a significant decrease of
the fEPSP response in relation to the fiber volley amplitude in TBI+Vehicle slices, and this was
rescued with AVL-3288 treatment (surgery x drug treatment interaction: F(1,20) = 4.45,
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Fig 3. Water maze. AVL-3288 treatment improved spatial memory in TBI animals. A) Representative swim tracks from acquisition day 4. B) Swim path length
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p = 0.0478). PPF was not significantly different between slices from sham animals or TBI ani-
mals treated with vehicle or AVL-3288 (S1 Fig). AVL-3288 treatment prior to and during high
frequency stimulation rescued the deficits in LTP maintenance. The initial phase of LTP, 1–5
min after high frequency stimulation (HFS), was similar across treatment groups. The mainte-
nance phase of LTP, 30–60 min after HFS, was significantly reduced in slices from TBI ani-
mals, and this was improved with AVL-3288 treatment (surgery x drug treatment interaction:
F(1,23) = 4.39, p = 0.047). No significant effects were observed with the level of depolarization
during HFS between treatment groups (S1 Fig). Additionally, synaptic fatigue during the HFS
was not significantly different between treatment groups (S1 Fig).
Discussion
In this study, we tested whether a positive allosteric modulator of the α7 nAChR, AVL-3288,
would reduce chronic cognitive deficits in a preclinical model of TBI. Using the moderate FPI
model in rats, we found that AVL-3288 treatment prior to training on several learning tasks
reduced memory deficits in cue and contextual fear conditioning, as well as spatial memory
retention in the water maze and spatial working memory. The effects of AVL-3288 were long-
lasting, with a short treatment of AVL-3288 during training on cue and fear conditioning
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resulting in a long-lasting improvement in retention of fear memory at 1 month post-training.
AVL-3288 treatment of hippocampal slices from TBI animals also improved LTP and synaptic
transmission in area CA1. Hippocampal atrophy, but not cortical atrophy after TBI was
reduced with AVL-3288. These results demonstrate that AVL-3288 is a promising therapeutic
to treat cognitive deficits after TBI.
AVL-3288 is a type 1 positive allosteric modulator that has recently been evaluated in a
phase 1 clinical trial for safety and pharmacokinetics in healthy subjects [51]. AVL-3288 has an
EC50 of 0.7 μM for human α7 nAChR in Xenopus oocytes, a brain plasma ratio of 2-fold and
half-life of 7.5 hr with oral dosing in mice [47]. The cardiovascular and respiratory safety pro-
file in humans has been evaluated and no adverse effects have been observed at doses up to 30
mg which results in plasma levels over 4-fold greater than that observed in the current study
[51]. AVL-3288 is selective for α7 nAChRs, having minimal activity towards other nAChRs, or
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the homologous GABAA α1β2γ2L receptor and the 5-HT3A receptor [47]. In this study, we
found that single administration of AVL-3288 at 0.3 mg/kg intraperitoneally reached brain lev-
els of 3 μM within 30 min of administration. This dose is 4-fold higher than the EC50 for
enhancing human α7 nAChR currents in Xenopus oocytes [47]. These results suggest that the
drug may have achieved levels high enough to modulate α7 nAChR conductance, although an
important limitation of this study is that we did not directly measure α7 nAChR currents.
Another important limitation of this study is that AVL-3288 levels were measured in naïve,
non-injured animals, but not in TBI animals which may alter the brain distribution and levels
of AVL-3288. Although the elimination rate in plasma in humans is known to be 3 hr, the rate
of clearance within the rat brain has not yet been determined [51]. Future studies using PET
ligands would be highly useful to measure brain distribution, target engagement, and rate of
clearance [51].
Since systemically administered AVL-3288 reached levels in the brain that could potentially
alter α7 nAChR currents by 30 min after treatment, we chose to treat animals 30 min prior to
training on each learning task. Each behavior task took 1–2 hr to complete daily, therefore this
drug administration protocol was chosen to optimize availability of the drug within the brain
at the time of learning. Administering AVL-3288 to be on board at the time of learning, but
not during retention, resulted in a persistent memory enhancing effect, improving both water
maze retention in the probe trial at 24 hr post-training and cue and contextual fear condition-
ing at both 24 hr and 1 month post-training. These results are in accordance with a previous
study demonstrating that AVL-3288 treatment in naïve rats enhanced social preference of a
juvenile, novel rat when assessed 24 hr after drug administration [56]. Further studies are
aimed at determining the duration of the effects of AVL-3288 treatment on memory enhance-
ment after TBI.
However, in contrast to other previous studies, we did not observe any nootropic effects of
AVL-3288 on sham animals during acquisition or retention of either the water maze task or
cue and contextual fear conditioning [47, 57, 58]. In these prior studies, AVL-3288 administra-
tion to naïve rats improved performance in the radial arm maze at a similar dose to what was
used in this study [47]. Repeated dosing with a higher concentration of AVL-3288 in naïve rats
also enhanced novel social preference [56]. Our differing results may be due to the spaced
treatment protocol since the sham and TBI animals only received 8 doses of AVL-3288 distrib-
uted over a 1 month time period. Alternatively, the memory paradigms that we chose may not
have been sensitive enough to detect a memory enhancing effect in sham animals, or acetyl-
choline levels were sufficient for maximal memory encoding in sham animals with these par-
ticular tasks.
Beyond hippocampal effects, we also observed a significant improvement in cue fear condi-
tioning. This result suggested that positive allosteric modulation of α7 nAChRs in TBI animals
may have resulted in a generalized improvement in learning and memory ability. Alternatively,
direct effects within the amygdala may explain this result. Less is known about how α7
nAChRs are affected in the amygdala as compared to the hippocampus. There is evidence in a
mild TBI model that surface expression and currents of α7 nAChRs are actually upregulated in
the amygdala after mild controlled cortical impact injury in rats [59]. These changes were asso-
ciated with a loss of GABAergic interneurons and increased excitability in the basolateral
amygdala. In the FPI model or controlled cortical impact, acetylcholine or α7 nAChR levels
are unaltered in the amygdala, suggesting that changes in acetylcholine or α7 nAChRs after
TBI within the amygdala may be model-dependent [60–62]. Further experiments are needed
to determine if AVL-3288 altered α7 nAChR currents within the amygdala with this TBI
model.
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Consistent with our behavioral results and previous studies evaluating positive allosteric
modulators of α7 nAChRs in naïve rats, AVL-3288 did not significantly alter basal synaptic
transmission in area CA1 in sham, non-injured animals [20, 63]. In TBI animals, we found
that AVL-3288 rescued the depression in synaptic strength as indicated by an improvement in
the fEPSP–fiber volley relationship. In addition, we found that the decaying LTP in slices from
TBI animals was rescued with AVL-3288 treatment. Further studies are needed to determine
the duration of the enhancement in LTP. Positive allosteric modulators and partial agonists of
α7 nAChRs facilitate LTP induction and convert short-term potentiation into non-decaying
LTP [20, 21, 64]. This facilitation of LTP induction is due to both pre- and postsynaptic mech-
anisms, by increasing glutamate release as characterized by an increase in miniature excitatory
postsynaptic current frequency, as well as increased postsynaptic depolarization leading to the
activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and cAMP response element-
binding protein (CREB) [64–66]. We observed no differences in PPF or the fiber volley ampli-
tude with TBI or AVL-3288 treatment, suggesting that the effects of AVL-3288 were post-syn-
aptic. These results are in partial accordance with a previous study using the controlled
cortical impact model that reported a recovery of the fiber volley amplitude by 7 days post-
injury [67]. Together, these results suggest that AVL-3288 may have improved learning and
memory ability in TBI animals by facilitating postsynaptic signaling, leading to the activation
of ERK1/2 and CREB, which are well known to be dysregulated and contribute to memory def-
icits after TBI [52, 68, 69].
An intriguing finding of our study is the reduction in hippocampal atrophy with AVL-3288
treatment of TBI animals. There are several potential mechanisms of why AVL-3288 had an
effect on hippocampal atrophy, but did not significantly alter cortical atrophy. There are
regional differences in the distribution of α7 nAChRs in the brain. α7 nAChRs are highly
expressed in the hypothalamus, moderately in hippocampus and striatum, and at low levels in
the midbrain, cortex and cerebellum [70, 71]. In the hippocampus, the α7 nAChR subtype is
the most highly expressed nAChR subtype, and the effects of nicotine are predominantly
through α7 nAChRs in the CA1 region [12, 16, 72, 73]. These studies suggest that AVL-3288
may have had a greater effect in the hippocampus than the cortex due to the distribution of
nAChR subtypes. In accordance with our results, a previous study found that intermittent nic-
otine administration rescued hippocampal-dependent learning impairments after controlled
cortical impact, but had no significant effects on reducing cortical lesion volume [34]. It is well
established that TBI results in chronic inflammation [74]. α7 nAChRs are expressed on micro-
glia and α7 nAChR agonists have known anti-inflammatory effects both within the brain and
the periphery [75–79]. We have observed a persistent upregulation of microglia within the
brain after 3–6 months post-injury and this increase was greater in the hippocampus than the
cortex [68]. Further experiments are needed to address the differential effects of AVL-3288 in
the hippocampus and cortex and determine if AVL-3288 may have reduced inflammation in
the hippocampus after TBI.
Several clinical trials for TBI have been implemented with limited success using the cholin-
esterase inhibitors rivastigmine, donepezil and galantamine [24, 40–42, 44, 80–83]. In Alzhei-
mer’s disease, cholinesterase inhibitors have also been tested in combination with memantine
with a few studies suggesting beneficial effects were greater with galantamine than with done-
pezil [84–87]. Donepezil is a cholinesterase inhibitor whereas galantamine is both a cholines-
terase inhibitor as well as a positive allosteric modulator of α4β2 and α7 nAChRs. These
studies support the possibility that the combinatorial treatment of AVL-3288 with memantine
may be a promising therapeutic approach for TBI [84, 88]. This approach has support at the
circuitry level given the cooperation of cholinergic and glutamatergic signaling to convert
short term plasticity into long-lasting LTP [89, 90]. Another approach that merits
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consideration is the FDA-approved smoking cessation drug varenicline. Varenicline is a high-
affinity partial agonist of the α4β2 nAChR and a full agonist of α7 nAChRs [91]. However, var-
enicline did not improve cognition in either patients with schizophrenia or mild-to-moderate
Alzheimer’s disease [92, 93]. This study and other studies solely targeting the α7 nAChR for
schizophrenia and Alzheimer’s disease further support the importance of considering combi-
natorial treatments [94]. Given the inflammatory processes still evident in the chronic recovery
phase of TBI, the combination of an anti-inflammatory treatment such as minocycline and
AVL-3288 may provide synergistic effects [68, 95, 96]. Minocycline in combination with N-
acetylcysteine (NAC) has shown efficacy in improving cognition in schizophrenia patients
[97].
AVL-3288 as a positive allosteric modulator of the α7 nAChR has a significant advantage
over clinically used cholinesterase inhibitors. Cholinesterase inhibitors result in homeostatic
changes within the brain due to increased levels of agonist by upregulation and/or downregu-
lation of receptor levels [54, 98–103]. An important advantage of AVL-3288 is that repeated
administration did not upregulate α7 nAChR levels, even when given once daily at 10 mg/kg
for 7 days [56]. Additionally, AVL-3288 has no effect on α7 nAChR currents unless an endoge-
nous agonist is present, preserving the endogenous spatial and temporal kinetics of cholinergic
modulation of learning and memory circuits [47]. As a type I positive allosteric modulator,
AVL-3288 does not affect the rapid desensitization kinetics of the α7 nAChR unlike type II
modulators [47]. Type II modulators block or slow desensitization and thus, have the potential
to be cytotoxic and disrupt synaptic/extra-synaptic plasticity mechanisms regulated by use-
dependent receptor desensitization [104, 105]. These advantageous properties of AVL-3288
and our findings indicate that positive allosteric modulation of α7 nAChRs with AVL-3288 is
a promising therapeutic strategy to facilitate cognitive recovery in chronic phase of TBI.
Supporting information
S1 Fig. PPF, depolarization levels during HFS, and synaptic fatigue during HFS were not
altered after TBI or AVL-3288 treatment. A) PPF ratio in response to stimulus intervals
from 12.5–250 msec. B) Total depolarization levels during HFS and steady-state depolarization
levels during the last 50 ms of HFS. C) Synaptic fatigue during HFS. Mean ± SEM, n = 5–6
slices/5-6 Sham+Vehicle animals, n = 5-6/5-6 Sham+AVL-3288 animals, n = 7 slices/6 TBI+-
Vehicle animals, n = 7–8 slices/7 TBI+AVL-3288 animals.
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